Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239550 | 0.76 | CYP1A2 (0.48) | KDM4EBACE1MAPTPDE3BPDE3A | |
| SCHEMBL13106403 | 0.76 | BACE1 (0.46) | KDM4EBACE1MAPTCASP3SENP8 | |
| SCHEMBL28798252 | 0.76 | BACE1 (0.55) | BACE1MAPTCASP3SENP8SENP7 | |
| SCHEMBL31391518 | 0.76 | BACE1 (0.46) | KDM4EBACE1MAPTCASP3SENP8 | |
| SCHEMBL1570979 | 0.76 | BACE1 (0.46) | BACE1KMT2ACYP1A2CYP2A6 | |
| SCHEMBL8531788 | 0.76 | HTR3A (0.47) | BACE1PDE3BPDE3ATDP1 | |
| SCHEMBL446874 | 0.76 | KDM4E (0.46) | KDM4EBACE1MAPTCASP3SENP8 | |
| SCHEMBL21988901 | 0.72 | MAP4K4 (0.54) | KDM4EBACE1MAPTPDE3BPDE3A | |
| SCHEMBL19032227 | 0.72 | APP (0.30) | — | |
| SCHEMBL19104136 | 0.72 | ALDH1A1 (0.42) | MAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. | 2022-09-20 | — | — | US | disclosed |
| EP-3787629-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-02-25 | — | — | US | disclosed |
| EP-2392572-B1 | Substituted diazepan compounds as orexin receptor antagonists | MERCK SHARP & DOHME (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2214676-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2150114-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009058238-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008143856-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008143856-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008069997-A1 | SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | KDM4E 1573/4885BACE1 200/4885MAPT 712/4885 |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | KDM4E 1278/4885BACE1 2517/4885MAPT 2163/4885 |
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | KDM4E 1278/4885BACE1 2517/4885MAPT 2163/4885 |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | KDM4E 2002/4885BACE1 233/4885MAPT 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.